Relevance to NICE guidance programmes

Advice

The use of bevacizumab at a dose of 7.5 mg/kg is not appropriate to be appraised by the NICE technology appraisal programme because it is off-label. It is not currently planned for any other NICE work programme.

NICE has issued a clinical guideline on Ovarian cancer: the recognition and initial management of ovarian cancer (NICE clinical guideline 122).

NICE has issued the following 2 technology appraisals on the licensed use of bevacizumab at a dose of 15 mg/kg in ovarian cancer:

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (NICE technology appraisal guidance 284). It does not recommend bevacizumab 15 mg/kg for this indication but people already receiving it in this way can continue treatment until they and their clinician consider it appropriate to stop.
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (NICE technology appraisal guidance 285). It does not recommend bevacizumab 15 mg/kg for this indication but people already receiving it in this way can continue treatment until they and their clinician consider it appropriate to stop.

NICE guidance also exists for the following licensed indications for bevacizumab in which it is not recommended:

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (NICE technology appraisal guidance 263)
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal guidance 118) (NICE technology appraisal guidance 242)
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (NICE technology appraisal guidance 214)
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (NICE technology appraisal guidance 212)
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (NICE technology appraisal guidance 118).